Bristol Myers Squibb Stock: Strong Growth Portfolio and Dividend Yield Position BMY Shares as a Value Play for North American Investors

Bristol Myers Squibb stands as a cornerstone in the biopharmaceutical industry, with its shares traded under the ticker BMY on the New York Stock Exchange in USD. The company focuses on discovering, developing, and delivering innovative medicines for serious diseases, particularly in oncology, hematology, immunology, and cardiovascular areas. For North American investors, BMY represents a blend of defensive stability and growth potential in a sector buoyed by demographic trends and medical innovation.

As of: 29.03.2026

By Elena Vargas, Senior Financial Editor at NorthStar Market Insights: Bristol Myers Squibb exemplifies resilient biopharma leadership, navigating patent cliffs through a robust pipeline of next-generation therapies.

Core Business Model and Strategic Foundations

Bristol Myers Squibb operates a diversified business model centered on blockbuster drugs and an emerging growth portfolio. Legacy products like Eliquis and Opdivo continue to drive the majority of revenues, while newer entrants are gaining traction. In 2024, total revenues reached $48.3 billion, up 7% from the prior year, with the growth portfolio contributing $22.6 billion, a robust 17% increase.

This dual structure mitigates risks from patent expirations. The company invests heavily in R&D, targeting high-unmet-need areas such as oncology and immunology. For investors, this model supports steady cash flows, evidenced by a consistent dividend policy.

Strategic acquisitions and partnerships have bolstered the pipeline. Bristol Myers emphasizes small molecules, biologics, and cell therapies like CAR-T, positioning it for long-term leadership in specialty medicines.

Financial Performance and Valuation Metrics

Recent financials highlight resilience despite GAAP challenges. Non-GAAP EPS stood at $1.15 for 2024, reflecting investments in growth areas, while the growth portfolio's expansion signals improving margins ahead.

Valuation analysis points to BMY trading at a discount. Intrinsic value estimates suggest fair value around $65 per share, compared to recent levels near $58.54 on NYSE in USD, implying significant upside potential.

Year-to-date performance shows a 9.5% share price return, with five-year total shareholder returns at 12.6%, underscoring long-term value creation. Dividend yield around 4.3% adds appeal for income-focused investors, with shareholders of record on April 2, 2026, eligible for $0.63 per share.

Analyst sentiment is mixed, with about 60% neutral ratings, but upward price target revisions like HSBC's to $60 indicate selective optimism.

Pipeline Highlights and Clinical Momentum

Bristol Myers Squibb's pipeline drives future growth. Positive data from mezigdomide in relapsed multiple myeloma demonstrated significant survival benefits without added disease progression risk, targeting a market with around 36,000 new U.S. cases in 2026.

Cobenfy's Phase 4 trial results affirmed symptom stability, safety, and tolerability for adults switching treatments, reinforcing its role in psychiatric care.

Oncology remains core, with Opdivo and newer assets expanding indications. Hematology and immunology portfolios benefit from CAR-T advancements and oral therapies, aligning with global demand for precision medicine.

These developments matter now as they de-risk the growth trajectory, potentially accelerating revenue diversification beyond mature products.

Relevance for North American Investors

North American investors find BMY particularly relevant due to its U.S.-centric revenue exposure and alignment with aging population trends. The U.S. accounts for a substantial portion of sales, benefiting from strong reimbursement dynamics and innovation incentives.

Dividend reliability appeals to retirement portfolios, while growth prospects suit those seeking healthcare exposure amid market volatility. Recent share price resilience, despite short-term dips, positions BMY as a defensive growth play.

Sector tailwinds, including geopolitical stability preferences for healthcare, enhance outperformance potential. HSBC notes lower AI disruption risks, drawing capital flows.

Competitive Landscape and Market Position

Bristol Myers competes with peers like Pfizer, Merck, and Roche in oncology and immunology. Its edge lies in the growth portfolio's 17% revenue surge, outpacing industry averages and offsetting legacy declines.

Strategic deals, such as with Oxford Biomedica, de-risk manufacturing and expand capabilities. Analyst coverage resumes with buy ratings signal confidence in profitability inflection.

Market share in key therapies remains solid, supported by a global footprint. For investors, this competitive moat supports sustained earnings power.

Risks and Key Questions for Investors

Patent cliffs pose near-term revenue pressure on blockbusters. GAAP losses in 2024 highlight execution risks in pipeline commercialization.

Regulatory hurdles and clinical trial outcomes remain uncertainties. Mixed analyst views reflect debates on growth sustainability versus legacy drags.

Macro factors like interest rates and healthcare policy shifts warrant monitoring. North American investors should watch earnings guidance, trial readouts, and dividend adjustments.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.